Vivimed Labs Limited (IN:VIVIMEDLAB)
:VIVIMEDLAB
Want to see IN:VIVIMEDLAB full AI Analyst Report?
Top Page
Vivimed Labs Limited
(VIVIMEDLAB)
Select Model
Select Model
Rating:39Underperform
Price Target:
₹6.00
▲(21.21% Upside)
Action:Downgraded
Date:01/21/26
The score is driven primarily by severe financial weakness (declining revenue, collapsing margins, ongoing losses, negative equity, and negative cash flows). Technical indicators also lean bearish with price below key moving averages and a negative MACD. Valuation is not supportive due to the negative P/E and no indicated dividend yield.
Positive Factors
Vertical integration across API, formulations, chemicals
Vivimed's integrated business model — developing, manufacturing and marketing APIs, finished dosage formulations and specialty chemicals — is a durable advantage. Vertical integration can protect margins, enable cross-selling, shorten product time-to-market, and reduce supplier dependence over months to years.
Negative Factors
Sustained revenue decline
A pronounced and ongoing revenue decline erodes scale economics and market presence. Over a 2-6 month horizon this trend constrains pricing leverage, reduces reinvestment capacity for R&D or capacity upkeep, and makes it harder to stem margin and cash-flow deterioration without strategic change.
Read all positive and negative factors
Positive Factors
Negative Factors
Vertical integration across API, formulations, chemicals
Vivimed's integrated business model — developing, manufacturing and marketing APIs, finished dosage formulations and specialty chemicals — is a durable advantage. Vertical integration can protect margins, enable cross-selling, shorten product time-to-market, and reduce supplier dependence over months to years.
Read all positive factors
Vivimed Labs Limited (VIVIMEDLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹543.09M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)0.41
Revenue Growth-35.33%
EPS Growth-65.64%
CountryIN
Employees607
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-2.21
Shares Outstanding82,913,910
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-1.17
Price to Sales (P/S)0.35
P/FCF Ratio-4.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vivimed Labs Limited Business Overview & Revenue Model
Company Description
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India, Mexico, Spain, Hungary, and interna...
How the Company Makes Money
Vivimed Labs Limited makes money primarily by selling (1) active pharmaceutical ingredients (APIs) and intermediates to other pharmaceutical manufacturers, (2) finished dosage formulations (finished medicines) sold through business-to-business (in...
Vivimed Labs Limited Financial Statement Overview
Summary
Income Statement
20
Very Negative
Balance Sheet
15
Very Negative
Cash Flow
25
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 676.14M | 1.16B | 1.49B | 1.87B | 2.37B | 8.61B |
| Gross Profit | 229.66M | 77.98M | 705.71M | -928.65M | 838.04M | 5.07B |
| EBITDA | 11.07M | -86.77M | -246.69M | -1.86B | -67.91M | 336.05M |
| Net Income | -183.94M | -319.61M | -454.46M | -3.29B | -676.50M | -777.95M |
Balance Sheet | ||||||
| Total Assets | 9.24B | 9.21B | 9.51B | 9.88B | 12.66B | 12.89B |
| Cash, Cash Equivalents and Short-Term Investments | 489.84M | 7.08M | 717.79M | 37.62M | 71.84M | 64.31M |
| Total Debt | 3.84B | 3.76B | 3.79B | 3.81B | 2.78B | 2.53B |
| Total Liabilities | 9.72B | 9.56B | 9.56B | 9.49B | 9.02B | 8.58B |
| Stockholders Equity | -479.63M | -351.69M | -54.61M | 394.23M | 3.64B | 4.32B |
Cash Flow | ||||||
| Free Cash Flow | -161.74M | -86.28M | -260.30M | 303.54M | -6.75B | 5.67B |
| Operating Cash Flow | -161.74M | -40.97M | -239.91M | 138.12M | -6.58B | 5.67B |
| Investing Cash Flow | 112.50M | -45.31M | 282.88M | -49.68M | 5.23B | 4.04B |
| Financing Cash Flow | 54.87M | 73.10M | -60.32M | -162.44M | -103.80M | -10.15B |
Vivimed Labs Limited Technical Analysis
Negative
4.95
Price Trends
6.61
Negative
8.66
Negative
6.89
Negative
Market Momentum
-0.08
Positive
46.93
Neutral
41.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIVIMEDLAB, the sentiment is Negative. The current price of 4.95 is below the 20-day moving average (MA) of 6.71, below the 50-day MA of 6.61, and below the 200-day MA of 6.89, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 46.93 is Neutral, neither overbought nor oversold. The STOCH value of 41.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VIVIMEDLAB.
Vivimed Labs Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | ₹1.35B | 111.96 | ― | ― | ― | ― | |
56 Neutral | ₹515.88M | 172.45 | ― | ― | -27.51% | 356.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ₹396.80M | -4.63 | ― | ― | -48.93% | -180.45% | |
39 Underperform | ₹543.09M | -2.21 | ― | ― | -35.33% | -65.64% |
* Healthcare Sector Average
IN:VIVIMEDLAB
Vivimed Labs Limited
6.55
1.65
33.67%
IN:BALAXI
Balaxi Pharmaceuticals Limited
24.49
-28.34
-53.64%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
31.70
-14.79
-31.81%
IN:LASA
Lasa Supergenerics Ltd.
7.92
-8.24
-50.99%
IN:PDPL
Parenteral Drugs (India) Limited
―
―
―
Vivimed Labs Limited Corporate Events
Vivimed Labs Posts Sharp Revenue Drop and Quarterly Loss in Q3 FY26
Mar 13, 2026
Vivimed Labs Limited reported its unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, following approval by its board of directors. The filings, made in compliance with India’s list...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.